No Data
No Data
Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024
Intellia Therapeutics (NTLA): Promising Gene Editing Stock With CRISPR-Cas9 Therapies
Looking Into Intellia Therapeutics's Recent Short Interest
Further Weakness as Intellia Therapeutics (NASDAQ:NTLA) Drops 23% This Week, Taking Three-year Losses to 88%
Goldman Sachs Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Cuts Target Price to $20
Citi Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Cuts Target Price to $19
No Data
No Data
三和巴菲特 : Have you cried today? Baby
YWCYAPWEICHOY 叶伟财 OP 三和巴菲特 :
YWCYAPWEICHOY 叶伟财 OP 三和巴菲特 : Laughed.
71179109 : Intellia - 20% yesterday